Infliximab therapy
Infliximab was administered intravenously 3-5 mg/kg bodyweight every
fourth to eight weeks after an initial induction phase. During the study
period a consensus document on infliximab therapy was
published20, recommending a dose of 5 mg/kg
bodyweight, and infusion every fourth week after the initial induction
phase. Patients included thereafter, were therefore treated according to
these recommendations, i.e. given a higher dose and more frequently than
patients included in the beginning of the study. For individual total
doses, see Supplement 2. During the study period, biosimilars appeared
on the market. Patients 1-4 and 12-13 received Remicade®, Merck Sharpe
&Dome AB (Sweden) while the rest received the biosimilar Inflectra®,
Pfizer AB (Sweden).